Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as KAI-9531, Ribupatide
Ribupatide (KAI-9531) · 6 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| Ribupatide: Dose 1 | EXPERIMENTAL | Participants will receive Dose 1 of ribupatide once weekly. |
| Ribupatide: Dose 2 | EXPERIMENTAL | Participants will receive Dose 2 of ribupatide once weekly. |
| Ribupatide: Dose 3 | EXPERIMENTAL | Participants will receive Dose 3 of ribupatide once weekly. |
| Ribupatide: Dose 4 | EXPERIMENTAL | Participants will receive Dose 4 of ribupatide once weekly. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to ribupatide once weekly. |
| Semaglutide | ACTIVE_COMPARATOR | Participants will receive semaglutide once weekly. |
| KAI-9531: Dose 1 | EXPERIMENTAL | Participants will receive Dose 1 of KAI-9531 once weekly. |
| KAI-9531: Dose 2 | EXPERIMENTAL | Participants will receive Dose 2 of KAI-9531 once weekly. |
| KAI-9531: Dose 3 | EXPERIMENTAL | Participants will receive Dose 3 of KAI-9531 once weekly. |
| KAI-9531: Dose 4 | EXPERIMENTAL | Participants will receive Dose 4 of KAI-9531 once weekly. |
| KAI-9531: Abdomen Injection Site | EXPERIMENTAL | Participants will receive KAI-9531 as a SC injection into the abdomen on Day 1 of either Treatment Period 1, 2 or 3. |
| KAI-9531: Thigh Injection Site | EXPERIMENTAL | Participants will receive KAI-9531 as a SC injection into the thigh on Day 1 of either Treatment Period 1, 2 or 3. |
| KAI-9531: Upper Arm Injection Site | EXPERIMENTAL | Participants will receive KAI-9531 as a SC injection into the upper arm on Day 1 of either Treatment Period 1, 2 or 3. |
| Ribupatide | EXPERIMENTAL | Participants will receive ribupatide once weekly. |
| Name | Type | Description |
|---|---|---|
| Ribupatide | DRUG | SC Injection |
| Placebo | DRUG | SC Injection |
| Semaglutide | DRUG | SC Injection |
| KAI-9531 | DRUG | SC Injection |
Key Inclusion Criteria: * Diagnosis of type 2 diabetes mellitus (T2DM). * Receiving stable therapy for T2DM for 3 months prior to Screening. This includes diet and/or exercise alone or in combination with any oral medication for T2DM treatment except for DPP-4 inhibitors. Participants can be treatm...
Top 20 of 31 competitors
Ribupatide is an investigational small molecule peptide developed by Kailera Therapeutics for metabolic conditions, including obesity, obesity with diabetes, and related renal impairment studies. It is also known as KAI-9531. It is given once weekly in clinical trials and is not yet approved for any indication.
Ribupatide targets the GLP-1 and GIP receptors, a dual incretin receptor mechanism. It belongs to the peptide class of molecules, reflected in the -tide naming. This dual GLP-1/GIP targeting is the basis for its investigation in obesity and obesity with diabetes.
Ribupatide is developed by Kailera Therapeutics, Inc., which trades under the ticker KLRA. The company is running the clinical program for the asset across obesity, obesity with diabetes, and renal impairment settings.
Ribupatide is in clinical development spanning Phase 1 through Phase 3. A Phase 1 renal impairment pharmacokinetic study is not yet recruiting, while two Phase 3 trials and one Phase 2 trial in obesity are currently recruiting. It is investigational and not approved.
Ribupatide trials include NCT07793929, a Phase 1 renal impairment pharmacokinetic study; NCT07458269, a Phase 2 obesity trial; NCT07284979, a Phase 3 obesity trial comparing it with semaglutide and placebo; and NCT07284901, a Phase 3 trial in obesity or overweight with diabetes.
Yes, Ribupatide and KAI-9531 refer to the same investigational compound from Kailera Therapeutics. KAI-9531 is the alternate code name used in some trial titles, such as the Phase 2 obesity study, while Ribupatide is the name used in the Phase 3 program.